Private Advisor Group LLC Acquires New Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Private Advisor Group LLC bought a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 12,743 shares of the company’s stock, valued at approximately $153,000.

Several other hedge funds have also recently added to or reduced their stakes in DCTH. Polar Asset Management Partners Inc. purchased a new position in Delcath Systems during the 3rd quarter valued at about $1,594,000. Principal Financial Group Inc. purchased a new position in Delcath Systems during the 3rd quarter valued at about $808,000. Virtu Financial LLC purchased a new position in Delcath Systems during the 3rd quarter valued at about $289,000. Baader Bank Aktiengesellschaft purchased a new position in Delcath Systems during the 4th quarter valued at about $204,000. Finally, Jane Street Group LLC purchased a new position in Delcath Systems during the 3rd quarter valued at about $110,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Price Performance

Shares of NASDAQ DCTH opened at $13.00 on Friday. The company has a market cap of $415.66 million, a PE ratio of -9.63 and a beta of 0.82. Delcath Systems, Inc. has a 12 month low of $3.70 and a 12 month high of $16.97. The company has a 50-day simple moving average of $14.40 and a 200-day simple moving average of $11.63.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same period in the prior year, the business posted ($0.48) earnings per share. On average, analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Craig Hallum lifted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, January 17th. HC Wainwright lifted their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Delcath Systems currently has an average rating of “Moderate Buy” and an average price target of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.